Skip to content
StockMarketAgent
Direct answer
CVS Health is a vertically integrated healthcare behemoth spanning health insurance (Aetna), pharmacy benefit management (Caremark), and retail pharmacy. While its scale provides robust and defensive cash flow generation, near-term headwinds from Medicare Advantage rates and retail margin compression weigh on profitability. Fair value range: low $62.5, high $112, with mid-point at $86.8.
Stock analysis

CVS CVS fair value $62–$112

CVS
By StockMarketAgent.AI team· supervised by
분석일: 2026-05-13다음 업데이트: 2026-08-13Methodology v2.4Review: automatedArchetype: Mature compounder
View archive
주가
$95.15
▼ -8.34 (-8.77%)
공정 가치
$87
$62–$112
등급
보유
confidence 88/100
상승 여력
-8.8%
upside to fair value
안전 마진
$73.79
MoS level · 15%
시가총액
$121.4B
P/E fwd 11.4
영어 원본으로 대체KO
번역하는 동안 영어 원본을 표시 중
이 리포트는 아직 번역되지 않았습니다. 번역 대기열이 따라잡으면 몇 분 후에 새로고침하세요.

§1 개요

  • Composite fair value $87 with high case $112.
  • Implied downside of 8.8% to fair value.
  • Moat 6.5/10 · confidence 88/100 · Mature compounder.
  • Currently screens above fair value, so patience matters more than entry speed.
Fair value
$87
Margin of safety
-9.6%
Confidence
88/100
Moat
6.5/10

Educational analysis only — not financial advice. Always do your own due diligence.

$95.15Price
Low $62.46
Mid $86.81
High $112.2

CVS Health is a vertically integrated healthcare behemoth spanning health insurance (Aetna), pharmacy benefit management (Caremark), and retail pharmacy. While its scale provides robust and defensive cash flow generation, near-term headwinds from Medicare Advantage rates and retail margin compression weigh on profitability.

  • Vertical integration creating a closed-loop
    Vertical integration creating a closed-loop value-based care model.
  • Immense scale in Pharmacy Benefit
    Immense scale in Pharmacy Benefit Management via Caremark.
  • Cycle upside
    Healthcare utilization normalizes post-pandemic while value-based care assets (Oak Street, Signify) mature and expand consolidated margins.

§2 베어 케이스

A combined shock of Medicare Advantage rate cuts and accelerated retail footprint deterioration. Under this stress test, free cash flow conversion drops, forcing a pause on share repurchases and straining the heavily indebted $80B balance sheet.

이 논제가 무너지는 경로

Severe MA Rate Rebasing

· Medium

Persistent medical cost inflation combines with unfavorable Medicare Advantage reimbursement updates, compressing insurance margins structurally above 88% MLR without offsetting premium increases.

FV impact
-25%
Trigger
12-18 Months

Retail Pharmacy Collapse

· High

The legacy retail pharmacy segment suffers from shrinking front-store foot traffic and generic drug pricing pressures, sharply limiting overall deleveraging capacity.

FV impact
-15%
Trigger
24-36 Months

Debt Deleveraging Failure

· Low

Failure to pay down acquisition debt out of FCF or dividend coverage ratio exceeding 70%, triggering a credit downgrade and cost-of-capital spike.

FV impact
-30%
Trigger
36 Months
모니터링할 조기 경보 신호
지표현재트리거 임계값
Aetna Medical Loss Ratio (MLR) expanding structurally above 88%.MonitorDeterioration versus the report thesis
Failure to pay down acquisition debt rapidly from free cash flow.MonitorDeterioration versus the report thesis
Dividend payout ratio exceeding 70% of Owner Earnings.MonitorDeterioration versus the report thesis
Front-store retail sales declining >3% year-over-year.MonitorDeterioration versus the report thesis
Loss of major Caremark PBM contracts due to transparency mandates.MonitorDeterioration versus the report thesis

§3 재무 이력

손익계산서 — 최근 6기
항목T−0T−1T−2T−3T−4CAGR
기간2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
매출$322.47B$357.78B$372.81B$402.07B+5.7%
매출총이익$54.50B$54.43B$51.40B$55.36B+0.4%
영업이익$16.29B$14.60B$9.70B$10.39B-10.6%
순이익$4.31B$8.34B$4.61B$1.77B-20.0%
EPS (희석)$5.95$3.26$6.47$3.66-11.4%
EBITDA$12.35B$18.20B$13.70B$9.86B-5.5%
R&D
판관비

품질 점수

OCF / 순이익
6.02×
>1은 이익의 질이 높음을 의미
회계 품질 게이트
Fail
섹터 조정 게이트
ROIC
2.7%
투하자본수익률
섹션 3

Numbers analysis

개인 구독자 — §4부터11개 섹션 더

전체 분석 읽기 — 11개 섹션 더.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

모든 커버 종목에 대한 전체 보고서
24개월 등급 아카이브
관심 목록 브리핑 + 등급 변경 알림
모든 언어로 PDF + DOCX 내보내기
무료 체험 시작
언제든지 취소 가능.
FAQ

CVS — frequently asked questions

  1. Based on our latest analysis, CVS screens modestly overvalued. The current price is $95.2 versus a composite fair-value midpoint of $86.8 (range $62.5–$112), which implies roughly 8.8% downside to the midpoint.
Related coverage

Names readers of CVS also follow

Same archetype: mature-compounder